Hee Jeong Cho, Jae-Cheol Jo, Yoo Jin Lee, Myung Won Lee, Do Young Kim, Ho Jin Shin, Sung Nam Im, Ji Hyun Lee, Sung Hwa Bae, Young Rok Do, Won Sik Lee, Min Kyung Kim, Jina Jung, Jung Min Lee, Ju-Hyung Kim, Dong Won Baek, Sang-Kyun Sohn, Joon Ho Moon
BACKGROUND/AIMS: Daratumumab has shown an encouraging antitumor effect in patients with multiple myeloma (MM), and was known to alter the immune properties by off-targeting immunosuppressive cells. Here, we aimed to evaluate the change in absolute lymphocyte count (ALC) as a surrogate marker for predicting survival outcomes of patients treated with daratumumab. METHODS: Between 2018 and 2021, the medical records of patients with relapsed/refractory MM (RRMM) treated with daratumumab monotherapy at 10 centers in South Korea were reviewed...
January 26, 2023: Korean Journal of Internal Medicine